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Background: To compare the overall survival of patients with hepatocellular carcinoma (HCC) who were treated
with lipiodol-based conventional transarterial chemoembolization (cTACE) with that of patients treated with drug-eluting
bead transarterial chemoembolization (DEB-TACE).
Methods: By an electronic search of our radiology information system, we identified 674 patients that received
TACE between November 2002 and July 2013. A total of 520 patients received cTACE, and 154 received DEB-TACE. In
total, 424 patients were excluded for the following reasons: tumor type other than HCC (n = 91), liver transplantation
after TACE (n = 119), lack of histological grading (n = 58), incomplete laboratory values (n = 15), other reasons
(e.g., previous systemic chemotherapy) (n = 114), or were lost to follow-up (n = 27). Therefore, 250 patients were
finally included for comparative analysis (n = 174 cTACE; n = 76 DEB-TACE).
Results: There were no significant differences between the two groups regarding sex, overall status (Barcelona
Clinic Liver Cancer classification), liver function (Child-Pugh), portal invasion, tumor load, or tumor grading (all p > 0.05).
The mean number of treatment sessions was 4 ± 3.1 in the cTACE group versus 2.9 ± 1.8 in the DEB-TACE group
(p = 0.01). Median survival was 409 days (95 % CI: 321–488 days) in the cTACE group, compared with 369 days
(95 % CI: 310–589 days) in the DEB-TACE group (p = 0.76). In the subgroup of Child A patients, the survival was
602 days (484–792 days) for cTACE versus 627 days (364–788 days) for DEB-TACE (p = 0.39). In Child B/C patients,
the survival was considerably lower: 223 days (165–315 days) for cTACE versus 226 days (114–335 days) for
DEB-TACE (p = 0.53).
Conclusion: The present study showed no significant difference in overall survival between cTACE and DEB-TACE in
patients with HCC. However, the significantly lower number of treatments needed in the DEB-TACE group makes it a
more appealing treatment option than cTACE for appropriately selected patients with unresectable HCC.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers, with an annual incidence of approximately
750,000 cases per year worldwide [1, 2]. Its incidence
continues to increase, mainly because of the increasing
incidence of hepatitis B virus (HBV) and hepatitis C
virus (HCV) infections [3]. The majority of patients are
diagnosed at intermediate or advanced clinical stages,
which excludes them from potentially curative treatments
such as resection, liver transplantation (LTX), or local
ablation. According to the Barcelona Clinic Liver Cancer
classification (BCLC), transarterial chemoembolization
(TACE) is the standard of care for patients with intermedi-
ate stage HCC (BCLC stage B) [1, 4, 5].
Drug-eluting bead transarterial chemoembolization
(DEB-TACE) has been widely commercially available
since 2006. Since then, DEB-TACE has become the de
facto standard in many centers worldwide; numerous in-
vestigators believe it to be more beneficial than conven-
tional TACE with lipiodol (cTACE) [6]. Some authors
recently reported median survival times of more than
4 years after DEB-TACE in well selected cohorts [7].
Nonetheless, evidence is limited regarding the direct
comparison of DEB-TACE and cTACE. Only four studies
were conducted in a randomized, prospective fashion
[8–11], and none of them showed a significant im-
provement of a hard endpoint. All other trials were
retrospective and mostly based on small patient sam-
ples or were lacking the assessment of hard endpoints
[12–17]. Two meta-analyses have been published so
far. Although they were based on nearly the same stud-
ies, their results were inconsistent. The first, published
in 2013, found no difference in tumor response be-
tween cTACE and DEB-TACE [18]. The second was
published in 2014, and found that DEB-TACE provided
better tumor response and better overall survival (OS)
at 1 and 2 years; however, OS did not differ between
the two methods at 6 months or at 3 years [19]. There-
fore, the purpose of the present study was to compare
the OS of a relatively large cohort of patients with
HCC treated with cTACE and DEB-TACE, taking into
account histological tumor grading, overall status, liver
function, and tumor load.
Methods
Study details and data acquisition
The present study is a retrospective, single-center, non-
randomized trial in which two parallel treatment
groups received either DEB-TACE or cTACE. The trial
was conducted based on the principles of the International
Conference on Harmonisation of Good Clinical Practice
guidelines and according to the Declaration of Helsinki in
its revised version. Institutional review board approval was
waived by the responsible Ethics Committee of RhinelandPalatinate, Germany given the retrospective study design
and analysis of clinical data. Patient records and informa-
tion were anonymized and de-identified prior to analysis.
The study included data from the doctoral thesis of one of
the authors (FP).
Our electronic radiology information system (RIS) was
searched to identify all patients treated with TACE at
our institution between November 2002 and July 2013,
and thus, 674 patients were included. The treatment of
the last included patient started in June 2012. All events
until the final evaluation date, 22 December 2013, were
recorded; therefore, the minimum follow-up period was
1.5 years. A total of 520 patients received cTACE, and
154 received DEB-TACE. In total, 397 patients were ex-
cluded because they had a tumor entity other than HCC
(n = 91), liver transplantation after TACE (n = 119), lack
of histological grading (n = 58), and incomplete laboratory
values (n = 15). Additionally, 114 patients were excluded
for other reasons as follows: essential data missing in the
patient record (n = 45), previous systemic chemotherapy
(sorafenib, erlotinib or others; n = 27), previous cisplatin
based TACE (n = 13), diffuse tumor (not measurable;
n = 10), previous selective internal radiation therapy
(SIRT) (n = 8), previous bland embolization (n = 6),
abortion of first TACE session (n = 2), previous irino-
tecan loaded DEB-TACE (n = 2), participation in
SPACE study (therefore the patient received either
additional sorafenib or placebo treatment; n = 1). Of
the remaining 277 patients, 27 were lost to follow-up.
Therefore, 250 patients were finally included for com-
parative analysis (n = 174 cTACE; n = 76 DEB-TACE)
(Fig. 1).
Patient stratification
Overall status, initial liver function, and tumor burden
are known to significantly affect the outcome of patients
with HCC after treatment [4, 20–22]. Herein, overall sta-
tus was represented by the BCLC classification, initial liver
function by the Child-Pugh score, and tumor burden by
the sum of the longest diameter (SLD) of the target lesions
and the status according to the Milan criteria (in or out).
Additionally, patients were stratified by histological
grading, which appears to have considerable impact on
survival after liver transplantation [23–25] and TACE
[11]. Patients who underwent resection or local ablative
therapy after TACE were excluded. To further eliminate
any bias, patients who underwent liver transplantation
were excluded as this procedure usually leads to a consid-
erably longer OS.
Treatment
Our interdisciplinary tumor board (Diagnostic and Inter-
ventional Radiology, Hepatobiliary/Transplant Surgery,
Hepatology) discussed the indication for TACE treatment
Fig. 1 CONSORT flow diagram
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admission as inpatients. Each pretherapeutic workup
included computed tomography (CT) or magnetic res-
onance imaging (MRI), up-to-date blood laboratory test
results, and clinical examination. Treatment was sched-
uled to take place the next day. TACE was conducted
by injecting the embolizing agent (10 mg Mitomycin C
[Mito-Medac®; Medac, Hamburg, Germany] emulsified
with 10 ml iodized oil [Lipiodol Ultra-Fluide®; Guerbet
Laboratories, Aulnay-Sous-Bois, France] or polyvinyl
alcohol particles [DcBeads® 500-700 μm, 300-500 μm,
and 100-300 μm; Biocompatibles, Farnham, UK; loaded
with 150 mg doxorubicin]) into the tumor-supplying
vessels as described elsewhere [8, 26]. Embolization
was stopped early in case of sluggish flow. Additional
bland embolization was not performed. After treat-
ment, all patients received a control CT on the same or
the next day to rule out extrahepatic displacement of
embolization material and other complications. If no
post-interventional complications occurred, patients
were discharged 1 or 2 days after treatment, depending
on their clinical condition. TACE was repeated every
6 weeks until no more viable tumor was detected by CT
or MRI [8, 10] or until any contraindications occurred.
Image analysis and patient status
The SLD was calculated according to mRECIST criteria
[27]. BCLC and Child-Pugh stages were calculated for
each patient on the basis of pre-interventional cross-
sectional imaging, respective blood test results, and doc-
umented clinical investigations [4, 21].Statistical analysis
Time-to-event data were analyzed using the Log-rank
test and the Kaplan-Meier method, and descriptive sta-
tistics of all other parameters were provided. The null
hypothesis was that there was no difference in OS for
patients with HCC treated with cTACE versus DEB-
TACE. The date of first treatment was applied to calcu-
late OS. A proportional hazards model was applied to all
variables to identify independent predictors of survival
and to calculate hazard ratios with their corresponding
95 % confidence intervals. Baseline characteristics were
compared using chi-squared tests and t-tests, depending
on the scale level. Number of TACE sessions and dur-
ation were analyzed using t-tests. Statistical Analysis
System (SAS®), version 9.2 (SAS Institute Inc., Cary NC,
USA) was used for analysis. Kaplan-Meier curves were
drawn using SPSS Statistics®, version 22 (IBM, Armonk,
USA). An independent statistician performed statistical
testing to avoid review bias (CR).
Results
There were no significant differences between the treat-
ment groups regarding sex, overall status (BCLC), portal
invasion, liver function (Child-Pugh), tumor load, or
tumor grading (all p > 0.05; Table 1). The only significant
differences between the two groups were for the distri-
bution of patients younger than 60 years (26.4 % vs.
14.5 % of patients; p = 0.04), cryptogenic liver cirrhosis
(2.9 % vs. 10.5 % of patients; p = 0.01) and prior curative
treatment (9.8 % vs. 22.4 % of patients; p = 0.01) for
cTACE and DEB-TACE, respectively.
Table 1 Baseline characteristics of both groups
cTACE (n = 174) DEB TACE (n = 76)
n % n % p
Patient demographics
Sex 0.17
Male 144 82.8 68 89.5
Female 30 17.2 8 10.5
Age (years) 0.04
<60 46 26.4 11 14.5
≥60 128 73.6 65 85.5
Etiology of liver cirrhosisa
Alcohol 0.15
Yes 86 49.4 30 39.5
No 88 50.6 46 60.5
HCV 0.91
Yes 47 27.0 20 26.3
No 127 73.0 56 73.7
HBV 0.21
Yes 14 8.0 10 13.2
No 160 92.0 66 86.8
NASH 0.29
Yes 10 5.7 2 2.6
No 164 94.3 74 97.4
Cryptogen 0.01
Yes 5 2.9 8 10.5
No 169 97.1 68 89.5
Prior curative treatment 0.01
Yes 17 9.8 17 22.4
No 157 90.2 59 77.6
Liver function/patient status
BCLC 0.21
A 30 17.2 8 10.5
B 59 33.9 34 44.7
C 77 44.3 30 39.5
D 8 4.6 4 5.3
ECOG 0.44
0 110 63.2 53 69.7
1 61 35.1 20 26.3
2 2 1.1 2 2.6
3 1 0.6 1 1.3
Portal invasion 0.25
Yes 36 20.7 11 14.5
No 138 79.3 65 85.5
Metastasis 0.66
Yes 5 2.9 3 3.9
Table 1 Baseline characteristics of both groups (Continued)
No 169 97.1 73 96.1
Child 0.48
A 103 59.2 51 67.1
B 64 36.8 22 28.9
C 7 4.0 3 3.9
Bilirubin (mg/dl) 0.40
<2 136 78.2 64 84.2
2-3 24 13.8 9 11.8
>3 14 8.0 3 3.9
Albumin (mg/dl) 0.54
>3.5 76 43.7 29 38.2
2.8-3.5 67 38.5 35 46.1
<2.8 31 17.8 12 15.8
INR 0.35
<1.7 172 98.9 76 100.0
1.7-2.3 2 1.1 0 0.0
>2.3 0 0.0 0 0.0
Ascites 0.55
None 118 67.8 61 80.3
Mild 38 21.8 11 14.5
Moderate to severe 18 10.3 4 5.3
Hepatic encephalopathy 0.26
None 173 99.4 75 98.7
Grade I-II 1 0.6 1 1.3
Grade III-IV 0 0.0 0 0.0
Tumor characteristics
Tumor grading 0.08
G1 80 46.0 34 44.7
G2 82 47.1 30 39.5
G3 12 6.9 12 15.8
Milan criteria 0.13
In 47 27.0 14 18.4
Out 127 73.0 62 81.6
SLD (cm) 0.93
<3 19 10.9 8 10.5
≥3 155 89.1 68 89.5
HBV hepatitis B virus, HCV hepatitis C virus, NASH nonalcoholic steatohepatitis,
BCLC barcelona clinic liver cancer classification, ECOG eastern cooperative
oncology group, INR international normalized ratio, SLD sum of the
longest diameter
a5 patients with HBV/HCV co-infection
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the cTACE group versus 2.9 ± 1.8 in the DEB-TACE group
(p = 0.01; Table 2). Consequently, the total duration of
TACE treatment was significantly longer in the cTACE
group than in the DEB-TACE group (217.4 ± 266.1 days
Table 2 TACE treatment characteristics and subsequent treatments
cTACE (n = 174) DEB TACE (n = 76) p
TACE treatment mean ± SD (range) mean ± SD (range)
TACE sessions per patient (n) 4.00 ± 3.09 (1–18) 2.96 ± 1.79 (1–9) <0.01
Total duration of TACE treatment (days) 217.4 ± 266.1 143.9 ± 171.5 0.01
Subsequent treatment na % na %
None 105 60.3 48 63.2 0.54
Crossover to other type of TACE 0.41
Yes 27 15.5 15 19.7
No 147 84.5 61 80.3
SIRT 0.09
Yes 11 6.3 1 1.3
No 163 93.7 75 98.7
Local ablation 0.18
Yes 12 6.9 2 2.6
No 162 93.1 74 97.4
Surgery 0.46
Yes 5 2.9 1 1.3
No 169 97.1 75 98.7
Sorafenib 0.77
Yes 25 14.4 12 15.8
No 149 85.6 64 84.2
Other systemic therapy 0.70
Yes 31 17.8 12 15.8
No 143 82.2 64 84.2
Patients receiving ≥2 treatments 1.00
Yes 16 9.2 7 9.2
No 158 90.8 69 90.8
TACE transarterial chemoembolization, SD standard deviation, SIRT selective internal radiotherapy
aSome patients received ≥2 subsequent treatments; therefore, the total number of treatments is greater than the total number of patients
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patients had subsequent treatment after the cessation of
TACE treatment: 69 in the cTACE group (40 %) and 28 in
the DEB-TACE group (37 %) (Table 2). After cTACE, the
69 patients received secondary treatment with DEB-TACE
(n = 27; 16 %), SIRT (n = 11; 6 %), local ablation (n = 12;
7 %), surgery (n = 5; 3 %), sorafenib (n = 25; 14 %), or other
systemic drugs (n = 31; 18 %); 16 of these patients received
two or more of these treatments. A total of 105 patients
(60 %) received no secondary treatment and either died
during TACE treatment or received best supportive care.
After cessation of DEB-TACE, 15 patients (20 %) received
secondary treatment with cTACE, SIRT (n = 1; 1 %), local
ablation (n = 2; 3 %), surgery (n = 1; 1 %), sorafenib (n =
12; 16 %), or other systemic drugs (n = 12; 16 %); 7 of these
patients received two or more of these treatments. Forty-
eight patients (63 %) received no secondary treatment
(Table 2). In summary, subsequent treatments did notdiffer significantly between the two groups (p > 0.05 in all
categories).
Median survival in the cTACE group was 409 days
(95 % CI: 321–488 days), compared with 369 days (95 %
CI: 310–589 days) in the DEB-TACE group (Fig. 2 and
Table 3; p = 0.76). The proportional hazards model re-
vealed that Child-Pugh stage and portal invasion were
the only independent predictors of survival (Table 4).
Therefore, we conducted an additional analysis of the
treatment effects according to Child-Pugh stage and por-
tal invasion. In the subgroup of Child A patients, the
median OS was 602 days (95 % CI: 484–792 days) for
cTACE versus 627 days (95 % CI: 364–788 days) for
DEB-TACE (Fig. 3; p = 0.40). Because of the small num-
ber of Child C patients (n = 7 in the cTACE group and
n = 3 in the DEB-TACE group), Child stages B and C
were combined for further analysis. The OS was consid-
erably lower in Child B/C patients: 223 days (95 % CI:
Fig. 2 Overall survival: cTACE vs. DEB-TACE (p = 0.76). “I” denotes censored values
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114–335 days) for DEB-TACE (Fig. 3; p = 0.53). As ex-
pected, patients with portal invasion exhibited signifi-
cantly shorter OS than patients without portal invasion
in each group (Fig. 4; p < 0.01). Nonetheless, when the
subgroups of patients with and without portal invasion
were analyzed separately, cTACE and DEB-TACE per-
formed equally well (Table 3). The OS in the subgroup
with portal invasion was 221 days (95 % CI: 143–285
days) in patients treated with cTACE versus 194 daysTable 3 OS of all patients, Child A and Child B/C subgroups
and patients with/without portal invasion
cTACE (n = 174) DEB-TACE (n = 76) p
OS (days) median (CI) median (CI)
All patients 409 (321–488) 369 (310–589) 0.76
Child A 602 (484–792) 627 (364–788) 0.40
Child B/C 223 (165–315) 226 (114–335) 0.53
Portal invasion
Yes 221 (143–285) 194 (97–310) 0.82
No 501 (410–607) 386 (325–634) 0.48
OS overall survival, CI confidence interval, DEB-TACE drug-eluting bead transarterial
chemoembolization, cTACE conventional TACE(97–310 days) in patients treated with DEB-TACE (p =
0.82). In patients without portal invasion, OS was
501 days (410–607 days) for cTACE compared with
386 days (325–634 days) for DEB-TACE; p = 0.48.
Discussion
Since 2006, when the first drug-eluting beads became
commercially available, DEB-TACE has become the de
facto standard in many centers, gradually replacing
lipiodol-based cTACE as the standard treatment forTable 4 Proportional hazards model to identify independent
predictors of survival






Unilobar vs. bilobar tumor 0.07
Number of nodules 0.09
Portal invasion <0.01
ECOG: eastern cooperative oncology group
Fig. 3 Overall survival: group 1 (cTACE) vs. group 2 (DEB-TACE), differentiated by Child stages A and B/C. P-values were 0.4 for Child A and 0.53
for Child B/C patients. “I” denotes censored values
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tific basis for that paradigm shift is poor. The PRECI-
SION V trial was by far the biggest study to compare
TACE with DEB-TACE, including 212 patients [8]; its
primary endpoint was tumor response measured by MRI
after 6 months. However, the lack of hard endpoints,
such as OS or progression-free survival (PFS), was criti-
cized afterwards [28]. At least some benefit was shown
for DEB-TACE over cTACE regarding objective response
in the subgroup of more advanced patients (Child-Pugh
B, ECOG 1, bilobar disease, and recurrent disease).
Reyes et al. published another prospective randomized
trial in 2009 [9]. Unfortunately, this phase II trial in-
cluded only 20 patients, too few to allow a definitive as-
sessment of the secondary endpoints, PFS and OS. Sacco
et al. published a series of 67 patients in which they pri-
marily investigated safety, toxicity, and tumor response
after 1 month; survival only served as a secondary end-
point [10]. The study by Van Malenstein et al. was also
restricted regarding the evaluation of toxicity and safety;
tumor response was measured only once 6 weeks after
the first treatment [11]. All other available studies were
retrospective [12–17]. Three of them relied primarily
on surrogate endpoints based on cross-sectional im-
aging [13, 14, 16], and two of these reported OS as a
secondary endpoint [13, 14]. One retrospective trialonly reported complications [29]. Only the studies by
Dhanasekaran et al., Scartozzi et al., and Wiggermann
et al. [12, 15, 17] primarily analyzed hard endpoints
such as PFS or OS. Nonetheless, the results of these
three studies differed considerably. Dhanasekaran et al.
and Wiggermann et al. each reported significant sur-
vival benefits of DEB-TACE, while the results of Scar-
tozzi et al. indicated the opposite. Notably, none of
these studies considered tumor grading, although it has
been reported to have a significant impact on the out-
come of patients with HCC after liver transplantation
[23–25], and TACE [11].
Llovet et al. and Lo et al. were able to demonstrate a
survival benefit of TACE versus symptomatic treatment
in 2002 [30, 31]. Nonetheless, in 2011 this statement in
general was heavily attacked by the Cochrane Review,
which concluded that a clear survival benefit of any type
of TACE has not yet been demonstrated [32]. Hence, we
decided to employ OS as a primary endpoint and believe
that future prospective studies should also be based on
hard endpoints such as OS or PFS [5, 33].
Altogether, the present study showed no significant
difference in OS between cTACE and DEB-TACE. Add-
itional analyses were conducted to take into account
Child-Pugh stages and the status of portal invasion; both
methods led to comparable survival times. During the
Fig. 4 Overall survival: group 1 (cTACE) vs. group 2 (DEB-TACE), differentiated by status of portal invasion. P-values were 0.82 for patients with
and 0.48 for patients without portal invasion. “I” denotes censored values
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was published. This trial was stopped early for futility
and found no significant difference between cTACE and
DEB TACE in the 2-year survival – further supporting
our OS data presented herein [34]. The main difference
in our study was the significantly lower number of treat-
ments needed in the DEB-TACE group compared with
cTACE, which is likely to enhance patient comfort. We
consider that these findings are highly relevant for clin-
ical decision-making. Patients can be exposed to a lower
number of treatment sessions, thus lowering their risk of
procedure-associated complications. Additionally, the
need for less treatment sessions makes DEB-TACE more
cost efficient than cTACE despite the considerable price
difference between lipiodol and drug-eluting beads.
The main weakness of this study is its retrospective,
single-centered and non-randomized design. We tried to
eliminate any bias by defining clear drop-out criteria
before analysis, which led to the exclusion of 63 % of
patients (Fig. 1). The remaining cTACE and DEB-TACE
cohorts exhibited no significant difference in any of the
factors known to significantly affect outcome. A relatively
high percentage of patients were classified as BCLC C. Ac-
cording to the BCLC scheme, stage C patients should
receive sorafenib therapy. Nonetheless, this is not
reflected in real clinical practice in most major liverdisease centers worldwide. Especially if a patient is clas-
sified as BCLC C because of having ECOG stage 1,
TACE is often preferred over sorafenib. As this was the
case in most of our BCLC C patients, we believe that
our collective represents the typical TACE patient quite
well. Another limitation is the use of two different che-
motherapeutic agents. Nonetheless, we believe that this
difference is negligible. To this day, no drug or combin-
ation of drugs has been proven better than any other
for the treatment of HCC in a randomized trial [35].
Only one non-randomized retrospective trial found that
cisplatin was superior to doxorubicin, but at the cost of
higher side effects [36]. We did not investigate compli-
cations as this was not the focus of our study, and this
is generally difficult to assess in a retrospective analysis.
Furthermore, we used DC Beads® ranging in diameter
from 100–300 μm to 500–700 μm. The larger drug-
eluting beads were primarily used at the beginning of
the treatment period; from 2010 on, we completely
switched to smaller beads of 100–300 μm, which we
believe preserve the patency of the arterial feeding ves-
sels, thereby allowing more repetitive treatments. From
2012 on, we switched to the even smaller DC Beads
M1® (70–150 μm). Nonetheless, it is questionable
whether the assumed positive effect of smaller beads
might have changed the present results.
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This study showed no significant difference in OS be-
tween cTACE and DEB-TACE in a large and comparable
cohort of patients with HCC. However, the significantly
lower number of treatments needed in the DEB-TACE
group might enhance patient comfort, possibly lower the
risk of procedure-associated complications among these
patients and improve cost-efficiency. Altogether, this
makes DEB-TACE a more appealing treatment option
than cTACE for appropriately selected patients with
unresectable HCC. Given the lack of a significant differ-
ence in OS between cTACE and DEB-TACE, researchers
seeking to enhance patient OS may consider focusing
further efforts on improving the proper selection of pa-
tients slated for TACE treatment in general.
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